← board
CVM
distress 8/10 · high distress / dilution risk$1.21-2%today-91% from 52w high
Lead: head and neck cancer
Revenue
pre-revenue
Liquidity
$2M
Runway
0.1 yrs
Shares 1y
+23%
Price & events
-81.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
+5.2%
1W
+18.6%
1M
-63.4%
3M
-79.2%
6M
-80.8%
1Y
-97.2%
2Y
-99.5%
5Y
-99.7%
All
Overview
- Market Cap
- $10.28M
- Volume
- 8.66K
- 52 Week Range
- $0.97 – $13.04
- Total Shares
- 8.49M
- Float Shares
- 8.22M
- Short %
- 1.56%
- % Held by Insiders
- 6.31%
- % Held by Institutions
- 4.44%
- RVOL
- 0.02x
- Beta
- 0.65
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2025-05-23partnershipnull · Closed public offering, gross proceeds $5M.SEC 8-K
- Q4 2024trial initiationsecondaryPhase 3Multikine · enrollment expected to beginSEC 8-K
- 2024-09-16fda agreementMultikine · FDA agreed to target selection criteria for confirmatory Registration Study of 212 patientsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — head and neck cancer
- PFEPFIZER INC$142.2B · D3
- CLDXCelldex Therapeutics, Inc.$2.7B · D3
- CMPXCompass Therapeutics, Inc.$366M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- CUECue Biopharma, Inc.$138M · D6
- CNTXContext Therapeutics Inc.$57M · D2
- PDSBPDS Biotechnology Corp$40M · D7
- BOLTBolt Biotherapeutics, Inc.$8M · D5
- AKTSAktis Oncology, Inc.— · D1
- ANLAdlai Nortye Ltd.— · D5
Recent news
- 2026-07-20$1.155 | Cel-Sci Corporation (CVM) Stock Price Today - Binance
- 2026-07-02CEL SCI CORP SEC Filing (Jul 2, 2026) | CVM ARS - Stock Titan
- 2026-07-01CEL SCI CORP (CVM) CFO receives 4,125-share stock grant in Form 4 - Stock Titan
- 2026-06-18CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
- 2026-06-16CEL-SCI (NYSE American: CVM) prices $2.5M best-efforts stock offering - Stock Titan
- 2026-06-15CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Stocktwits
- 2026-01-26Why DID CVM Shares Rally Over 7% Today? - Stocktwits
- 2026-01-26Kersten Geert buys Cel Sci (CVM) shares worth $200000 - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.